Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|November 6, 2018
Pharmatech Associates Launches International Contracting and Services Company
Author(s)Pharmaceutical Technology Editors
Pharmatech Associates International Contracting and Services is a new company headquartered in Doha, Qatar, that will provide product development, facility design, and construction for high quality pharmaceutical and biotech products at low cost.
Advertisement
Pharmatech Associates launched Pharmatech Associates International Contracting and Services (PAICS), a new company with headquarters in Doha, Qatar, the company announced in a Nov. 4, 2018 press release. PAICS provides a global, single-source platform for clients and investors from which next-generation pharmaceutical facilities can be designed, constructed, and operated anywhere in the world.
“PAICS imagines a world where pharmaceutical innovators know no bounds. Neither the high costs of construction nor lack of local manufacturing expertise should prohibit opportunities for growth and expansion,” said Bikash Chatterjee, president and chief science officer, Pharmatech Associates, in the press release. “We are extending the Pharmatech brand-associated with the highest quality standards-to create new, local facilities that integrate product and process development, compliance, regulatory affairs, and validation from drug design to commercialization.”
PAICS, with its strategic alliance with FAL Group of Doha, Qatar, will provide drug and product development solutions, integrating facility design and construction; manufacturing equipment selection; quality management system (QMS) integration; management staffing and training; facilities commissioning and qualification; facilities, drug, and product regulatory registration; and commercial operations management.
“From our decades of industry experience serving clients, we created PAICS as a single-source solution to producing capital-efficient life science facilities for product development, manufacturing, and quality control assurance with fully integrated, optimized QMS,” said Warren G. Baker, CEO and chairman of Pharmatech Associates, in the press release. “PAICS heralds an era of local design and management of new facilities purpose-built to comply with all regulatory requirements to meet the highest standards of the FDA, EMA [European Medicines Agency], and WHO [World Health Organization].”
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5